Fibrogen regains all rights to roxadustat from astrazeneca in the united states and other astrazeneca territories, except china and south korea

The fibrogen – astrazeneca china agreement for roxadustat remains in place fibrogen to explore licensing opportunities for roxadustat san francisco, feb. 26, 2024 (globe newswire) -- fibrogen, inc. (nasdaq: fgen) announced today that fibrogen and astrazeneca have agreed to terminate the u.s./row roxadustat collaboration agreement entered into on july 30, 2013, under which astrazeneca held development and commercialization rights in the united states and other territories outside of china not licensed to astellas pharma inc. pursuant to a termination and transition agreement entered into between the parties, astrazeneca is returning all u.s./row roxadustat rights to fibrogen (with the exception of south korea) and providing certain assistance during a transition period. fibrogen's collaboration agreement with astrazeneca for roxadustat in china remains in place and roxadustat remains the leader in china by brand value share in the chronic kidney disease (ckd) anemia category.
FGEN Ratings Summary
FGEN Quant Ranking